MHR
IONS icon

Matthew Hamilton Rosenberg’s Ionis Pharmaceuticals IONS Stock Holding History

Matthew Hamilton Rosenberg’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-20
Closed -$801 – 832
2024
Q3 		$801 Hold
20
– – ﹤0.01% 786
2024
Q2 		$942 Hold
20
– – ﹤0.01% 741
2024
Q1 		$879 Hold
20
– – ﹤0.01% 783
2023
Q4 		$1.01K Hold
20
– – ﹤0.01% 790
2023
Q3 		$907 Hold
20
– – ﹤0.01% 793
2023
Q2 		$821 Hold
20
– – ﹤0.01% 802
2023
Q1 		$715 Hold
20
– – ﹤0.01% 851
2022
Q4 		$755 Hold
20
– – ﹤0.01% 841
2022
Q3 		$1K Buy
+20
New +$843 ﹤0.01% 819

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
TBC
Tweedy, Browne Co Stamford, Connecticut $1.26B AUM 33.88% 1-Year Est. Return

Matthew Hamilton Rosenberg's IONS Position: Q4 2024 in Review

Matthew Hamilton Rosenberg sold out of Ionis Pharmaceuticals (IONS) in Q4 2024, closing a stake of 20 shares — an estimated $801 sold.

Matthew Hamilton Rosenberg first reported a position in IONS in Q3 2022 and held it in 9 quarters. The position peaked at $1.01K in Q4 2023. 354 funds tracked by Wall St. Rank hold IONS as of Q4 2024.

  • Matthew Hamilton Rosenberg reported no remaining Ionis Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Matthew Hamilton Rosenberg sold 20 Ionis Pharmaceuticals shares in Q4 2024, an estimated $801.
  • Matthew Hamilton Rosenberg first reported a position in Ionis Pharmaceuticals in Q3 2022 and held it in 9 quarters.
  • Matthew Hamilton Rosenberg's Ionis Pharmaceuticals position peaked at $1.01K in Q4 2023.
  • 354 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2024.

Based on Matthew Hamilton Rosenberg's 13F filing for Q4 2024, filed 14 Jan 2025.